benzo[b][1]benzazepine-11-carboxamide;5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: benzo[b][1]benzazepine-11-carboxamide;5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
• 化学式: C30H24N4O3
• 分子量: 488.5
• InChiKey: PVUOCEVJCWTYQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.03
• 重原子数：
  37
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.03
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS<br/>[FR] AMIDES PIPÉRIDINYL PYRIMIDINE EN TANT QU'OUVREURS DU CANAL POTASSIQUE KO7
  申请人：PFIZER

  公开号：WO2012004698A1

  公开（公告）日：2012-01-12

  The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.

  本发明涉及公式（I）所述的化合物或其药学上可接受的盐，包括该化合物或其药学上可接受的盐的制药组合物以及治疗或制造用于治疗中枢神经系统疾病，障碍或病况的药物，包括双相情感障碍，抑郁障碍，焦虑障碍，认知障碍，疼痛障碍，泌尿生殖障碍和癫痫等其他疾病，障碍或病况，可以作为单一治疗或与另一种活性药物成分联合使用。
• Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers
  申请人：Claffey Michelle Marie

  公开号：US20130150391A1

  公开（公告）日：2013-06-13

  The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.

  本发明涉及一种式（I）的化合物或其药学上可接受的盐，包括含有式（I）的化合物或其药学上可接受的盐的制药组合物，以及治疗中枢神经系统疾病、失调或症状的方法，包括双相情感障碍、抑郁症、焦虑症、认知障碍、疼痛障碍、泌尿生殖障碍和癫痫等疾病、失调或症状，可以作为单一疗法或与其他活性药物成分联合使用的制药品的制造方法。
• Pyrimidones for Treatment of Potassium Channel Related Diseases
  申请人：Sakurada Isao

  公开号：US20130184294A1

  公开（公告）日：2013-07-18

  The present invention relates to compounds of Formula I as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.

  本发明涉及公式I所述的化合物或其药学上可接受的盐，包括公式I化合物或其药学上可接受的盐的制药组合物以及治疗中枢神经系统疾病、失调或病症的方法，包括双相情感障碍、抑郁症、焦虑症、认知障碍、疼痛障碍、泌尿生殖系统障碍和癫痫等其他在此处讨论的疾病、失调或病症，作为单一治疗或与另一种活性药物成分联合使用。
• BROMHEXINE FOR THE TREATMENT OF PAIN
  申请人：Kern, Kai-Uwe

  公开号：EP3415143A1

  公开（公告）日：2018-12-19

  The invention relates to bromhexine or a salt thereof for treating acute or chronic pain in a patient. In particular, the invention relates to bromhexine or a salt thereof for use in treating nociceptive pain, neuropathic pain and or dysfunctional pain. The invention further relates to a topical pharmaceutical composition comprising bromhexine or a salt thereof and to a composition or a topical pharmaceutical composition comprising bromhexine or a salt thereof for treating acute or chronic pain.

  本发明涉及用于治疗患者急性或慢性疼痛的溴己新或其盐。特别是，本发明涉及用于治疗痛觉疼痛、神经性疼痛和或功能障碍性疼痛的溴己新或其盐。本发明进一步涉及一种包含溴己新或其盐的外用药物组合物，以及一种包含溴己新或其盐的用于治疗急性或慢性疼痛的组合物或外用药物组合物。
• Methods
  申请人：INTRA-CELLULAR THERAPIES, INC.

  公开号：US11053245B2

  公开（公告）日：2021-07-06

  Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.

  将特定的取代杂环融合γ-咔啉化合物作为药物，用于治疗激动、攻击行为、创伤后应激障碍或冲动控制障碍。